Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
Advancing type 1 diabetes therapy: autologous islet transplant breakthrough
The first autologous transplantation of chemically induced pluripotent stem-cell-derived islets (CiPSC islets) achieved year-long insulin independence for a type 1 diabetes patient. The procedure, performed by Wang and colleagues at Nankai University, involved reprogramming the patient's own adipose tissue to avoid immune rejection and was less invasive. The patient showed significant improvements in blood glucose levels and HbA1c, achieving complete insulin freedom within 75 days post-transplantation. This breakthrough highlights advancements in regenerative medicine and the potential for personalized cell therapies.
Related Clinical Trials:
Development of patient-derived lymphomoids with preserved tumor architecture for ...
Developed a system using the air–liquid interface method to maintain lymphoma tissues ex vivo, preserving viability, proliferation, structure, and cellular composition. Optimized conditions using RGD-hydrogel and BAFF, maintaining B-cell viability and tissue architecture for up to 1 week. Human lymphomoids retained cell heterogeneity and could be used to test sensitivity to different compounds, with results largely matching clinical responses.
ASH 2024: Pharmacists Play Key Role in Incorporating Venetoclax, Blinatumomab for ...
Amir Ali, PharmD, discusses abstracts on shorter venetoclax durations in AML and blinatumomab in B-ALL, highlighting their efficacy and implications for treatment. Ali emphasizes the role of pharmacists in optimizing treatment durations and managing side effects, noting the potential for shorter venetoclax regimens and the benefits of blinatumomab pre-HSCT, especially for Hispanic patients.
Ziftomenib Shows Promise in Treatment-Resistant AML
Ziftomenib, an oral selective menin inhibitor, shows promising results in treating treatment-resistant acute myeloid leukemia (AML), particularly in cases with NPM1 mutations or KMT2A rearrangements. Clinical trials indicate high complete remission rates, with manageable safety profiles and potential for combination therapies. The FDA's Breakthrough Therapy designation aims to expedite its development and review.
PMV Pharmaceuticals, Inc. SEC 10-Q Report
PMV Pharmaceuticals' Q3 2024 Form 10-Q reports $21.9M in operating expenses, $19.2M net loss, and $0.37 net loss per share. The company is advancing PC14586 through clinical trials, received FDA Fast Track Designation, and restructured with a 30% workforce reduction. PMV expects to fund operations through 2026 with $197.9M in cash and equivalents.
myeloMATCH precision medicine trials in myelo
Four leading cancer research organizations in the U.S. and Canada open patient enrollment for myeloMATCH, a precision medicine clinical trial portfolio for adults with AML or MDS. The trials, designed by the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG Cancer Research Network, aim to accelerate precision medicine in myeloid malignancies and develop new therapies. Three treatment trials are now open, with more in development, and researchers hope to enroll 5,000 or more patients. myeloMATCH offers advanced biomarker testing at no cost, with results returned within three days, and structured into four tiers based on the patient's treatment journey.
Related Clinical Trials:
Glutaminase Inhibition Plus Azacytidine Promising for Advanced MDS
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.
Editorial: Novelties in Acute Myeloid Leukemia: From Biology to Clinical Applications
Advances in AML biology reveal new prognostic biomarkers, therapeutic strategies, and CAR-T cell efficacy, focusing on transcriptomic signatures, autophagy, lysosome-related genes, SET-CAN/NUP214 fusion, RAS mutations, and single-cell sequencing.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath